233 related articles for article (PubMed ID: 34381843)
1. Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents.
Mills AM; Schulman KL; Fusco JS; Wohlfeiler MB; Priest JL; Oglesby A; Brunet L; Lackey PC; Fusco GP
Open Forum Infect Dis; 2021 Aug; 8(8):ofab363. PubMed ID: 34381843
[TBL] [Abstract][Full Text] [Related]
2. Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.
Mills AM; Brunet L; Fusco JS; Wohlfeiler MB; Garris CP; Oglesby AK; Mrus JM; Lackey PC; Fusco GP
Infect Dis Ther; 2020 Mar; 9(1):41-52. PubMed ID: 31701370
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy and liver disorders in the OPERA
Wohlfeiler M; Mounzer K; Brunet L; Fusco J; Vannappagari V; Curtis L; Payvandi N; Aboud M; Hsu R; Lackey P; Fusco G
Ther Adv Drug Saf; 2020; 11():2042098620976953. PubMed ID: 33343858
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study.
Santos JR; Casadellà M; Noguera-Julian M; Micán-Rivera R; Domingo P; Antela A; Portilla J; Sanz J; Montero-Alonso M; Navarro J; Masiá M; Valcarce-Pardeiro N; Ocampo A; Pérez-Martínez L; García-Vallecillos C; Vivancos MJ; Imaz A; Iribarren JA; Hernández-Quero J; Villar-García J; Barrufet P; Paredes R;
Front Cell Infect Microbiol; 2023; 13():1187999. PubMed ID: 37434782
[TBL] [Abstract][Full Text] [Related]
5. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort.
Fusco J; Henegar C; Quinlivan EB; Vannappagari V; Aboud M; Smith K; Fusco G
Curr HIV Res; 2019; 17(4):266-276. PubMed ID: 31560291
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
7. Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1.
Donga P; Emond B; Rossi C; Bookhart BK; Lee J; Caron-Lapointe G; Wei F; Lafeuille MH
Clinicoecon Outcomes Res; 2023; 15():579-591. PubMed ID: 37521004
[TBL] [Abstract][Full Text] [Related]
8. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
[TBL] [Abstract][Full Text] [Related]
9. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
[TBL] [Abstract][Full Text] [Related]
10. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
Hsu R; Fusco J; Henegar C; Mounzer K; Wohlfeiler M; Vannappagari V; Aboud M; Curtis L; Fusco G
Ther Adv Drug Saf; 2018 Dec; 9(12):675-686. PubMed ID: 30546862
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
[TBL] [Abstract][Full Text] [Related]
12. Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
Mounzer K; Brunet L; Fusco JS; Mcnicholl IR; Diaz Cuervo H; Sension M; Mccurdy L; Fusco GP
Open Forum Infect Dis; 2022 Mar; 9(3):ofac018. PubMed ID: 35169590
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
Benson P; Kuretski J; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Brogan AP; Patarroyo J; Oglesby A
Infect Dis Ther; 2024 Apr; 13(4):875-889. PubMed ID: 38570444
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
Davy-Mendez T; Napravnik S; Zakharova O; Wohl DA; Farel CE; Eron JJ
AIDS; 2019 Jun; 33(7):1187-1195. PubMed ID: 30870198
[TBL] [Abstract][Full Text] [Related]
15. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
[TBL] [Abstract][Full Text] [Related]
17. Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA
Pierone G; Henegar C; Fusco J; Vannappagari V; Aboud M; Ragone L; Fusco G
J Int AIDS Soc; 2019 Dec; 22(12):e25418. PubMed ID: 31802641
[TBL] [Abstract][Full Text] [Related]
18. Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya.
Aoko A; Pals S; Ngugi T; Katiku E; Joseph R; Basiye F; Kimanga D; Kimani M; Masamaro K; Ngugi E; Musingila P; Nganga L; Ondondo R; Makory V; Ayugi R; Momanyi L; Mambo B; Bowen N; Okutoyi S; Chun HM
EClinicalMedicine; 2023 Sep; 63():102166. PubMed ID: 37649807
[TBL] [Abstract][Full Text] [Related]
19. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
[No Abstract] [Full Text] [Related]
20. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Suárez-García I; Moreno C; Ruiz-Algueró M; Pérez-Elías MJ; Navarro M; Díez Martínez M; Viciana P; Pérez-Martínez L; Górgolas M; Amador C; de Zárraga MA; Jarrín I;
AIDS Res Ther; 2020 Jul; 17(1):45. PubMed ID: 32690099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
